Purposes: Surveying serum Gamma Glutamyl Transferase levels followed by the grade of heart failure patients (according to the New York Heart Association - NYHA) due to ischemic heart disease and evaluating the relationship between serum Gamma Glutamyl Transferase levels with Heart failure staging and laboratory tests (NT-proBNP levels, (EF) ejection fraction) in heart failure patients due to ischemic heart disease. Method: Study design: a cross - sectional descriptive study, including 140 patients were treated at the Department of Cardiology, Hue Central Hospital, from March 1st, 2021, to May 30th, 2022. They were divided into two groups: the group with heart failure (n = 70) and the control group without heart failure (n = 70). Result: The serum Gamma Glutamyl Transferase concentration increased significantly in the group of patients with heart failure (56 U/l) compared with the control group (34 U/l) (p <
0.05). The median value of serum Gamma Glutamyl Transferase concentrations in heart failure stages II, III, and IV in the study according to NYHA classification was 53 U/l, 56 U/l and 286 U/l, respectively. Serum Gamma Glutamyl Transferase levels were positively correlated with the severity of heart failure according to the NYHA class, (r = 0.49
p <
0.001). GGT had good value in predicting the severity of heart failure (AUC = 0.869
95% CI: 0.767 - 0.938), the best cutoff GGT ≥ 51 U/l with sensitivity: 81.25%, specificity: 77.27%
Gamma Glutamyl Transferase concentration had a moderate positive correlation with NT-proBNP concentration (r = 0.42
p = 0.0004) and had a negative correlation with left ventricular ejection fraction (LVEF), (r = - 0.3
p = 0.013). Conclusion: With a high diagnostic value, giving fast and accurate results of Gamma Glutamyl Transferase levels in various degrees of chronic heart failure, the Gamma Glutamyl Transferase test should be used as a good support test in the diagnosis and prognosis in patients with heart failure due to ischemic heart disease